Eli Lilly will build half the factory it promised in Germany, and send the rest of the money to the United States.
The plant was announced as a 2.3 billion euro (roughly 2.5 billion dollar) injectable site in Alzey, in Germany's Rhineland-Palatinate, built to fill pens of the weekly shots that are now Lilly's biggest business. The company confirmed this week that it is cutting the investment by about half and dropping the planned headcount from around 1,000 jobs to 500. The site still opens in 2027, but at reduced capacity, with any further expansion on hold. The reason Lilly gave is Germany's proposed healthcare cost-control reform, a rebate that would automatically lower what the state pays for a drug as its use climbs. For a class of medicine whose defining feature is that demand keeps climbing, that is close to the worst possible formula.
The drugs in question are GLP-1 receptor agonists, the injected hormone-mimics that blunt appetite and lower blood sugar. The Alzey line was built to supply Lilly's tirzepatide ↗, sold as Mounjaro for diabetes and Zepbound for obesity, alongside the older weekly drug dulaglutide ↗, sold as Trulicity. Tirzepatide pulls on two gut-hormone receptors at once, the GLP-1 receptor ↗ and the GIP receptor ↗; dulaglutide pulls on the GLP-1 receptor alone. Both ship as injectables, which is exactly the capacity Lilly is now redirecting across the Atlantic.
CEO Dave Ricks was blunt about where it goes. "Europe isn't completely off the table, but the U.S. makes the most sense," he told Handelsblatt, in reporting picked up by Pharma Manufacturing ↗. The redirected capital most likely lands at Lilly's existing American footprint, where the company has spent the past two years announcing domestic plants in the billions.
Lilly is not the only one walking back. Boehringer Ingelheim has also pulled planned German investment, and Reuters reported that Berlin is now rethinking the price reforms ↗ that prompted the retreat. That is the real story under the plant-by-plant numbers. A continent that wants both lower drug prices and the factory jobs that come with making those drugs is learning that the two goals pull against each other. Write a law that shrinks the reward for selling more of a successful medicine, and the building that makes it shrinks to match.
For peptidemodel, the two molecules at the center of the decision sit on live cards, tirzepatide and dulaglutide, both built against the same GLP-1 receptor that turned a regional German plant into a transatlantic bargaining chip. The science that made these drugs work is settled. Where the world agrees to manufacture them is not.